Tejara Capital Ltd disclosed a buy of 69,700 Teleflex (TFX 1.84%) shares in a February 5 SEC filing, with an estimated transaction value of $8.45 million based on quarterly average pricing.
What happened
According to a Securities and Exchange Commission (SEC) filing dated February 5, Tejara Capital Ltd increased its stake in Teleflex by 69,700 shares. The estimated value of the additional shares acquired is approximately $8.45 million, calculated using the average closing price for the fourth quarter of 2025. The fund’s total position value in Teleflex rose by $8.50 million quarter over quarter, a figure that includes share additions and price fluctuations.
What else to know
This buy increased the Teleflex stake to 2.23% of Tejara’s 13F assets under management as of December 31.
Top five holdings after the filing:
- NYSE:DEC: $29.07 million (12.1% of AUM)
- NASDAQ:GLNG: $13.73 million (5.7% of AUM)
- NYSE:SDRL: $12.73 million (5.3% of AUM)
- NYSE:NE: $9.85 million (4.1% of AUM)
- NASDAQ:MRVI: $9.82 million (4.1% of AUM)
As of February 4, Teleflex shares were priced at $106.00, down a steep 38.7% over the past year and well underperforming the S&P 500’s roughly 14% gain in the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of 2/4/26) | $106.00 |
| Market capitalization | $4.68 billion |
| Revenue (TTM) | $3.19 billion |
| Dividend yield | 1.28% |
Company snapshot
- Teleflex offers single-use medical devices for critical care, surgical, interventional, anesthesia, urology, and respiratory applications, with key product lines including Arrow catheters, UroLift System, and vascular closure devices.
- The company generates revenue primarily through the design, manufacturing, and global distribution of proprietary medical devices used in hospitals and healthcare settings.
- It serves hospitals, healthcare providers, medical device manufacturers, and home care markets worldwide.
Teleflex is a diversified medical device company specializing in devices for critical care and surgical procedures, with a global presence and a broad portfolio of proprietary products. The company leverages innovation and a strong distribution network to address the needs of hospitals and healthcare providers. Its scale and focus on single-use, high-demand medical products support a resilient business model within the healthcare sector.
What this transaction means for investors
Teleflex is in the middle of a messy but intentional transition, and the stock price has reflected the discomfort. Shares are down nearly 39% over the past year even as the business continues to generate real operating growth.
In the most recent quarterly release, Teleflex posted GAAP revenue of $913 million, up 19.4% year over year, with adjusted diluted EPS rising to $3.67 (compared to $3.49 one year prior). While the headline loss was driven by impairment charges tied to portfolio reshaping, interventional and vascular categories delivered standout growth, and management narrowed full-year revenue guidance and lifted adjusted EPS expectations to a $14.00 to $14.20 range.
That context matters when you look at the portfolio this position sits within. Tejara’s top holdings skew toward volatile energy, shipping, and biotech names, making Teleflex one of the more defensively structured businesses in the mix. Single-use medical devices, recurring hospital demand, and global distribution offer a very different risk profile than the fund’s higher-beta positions.
